Showing 231-240 of 381 results for "".
- New Biomarkers May Help Advance Melanoma Detectionhttps://practicaldermatology.com/news/new-biomarkers-may-help-advance-melanoma-detection/2461539/New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia. “Melanomas exhibit a wide range of sizes, shapes and growth, which can resemble numerous benign and other malignant skin lesions,&
- Case Study: Ulcer at Corner of Mouth May Be First Sign of Monkeypox Virushttps://practicaldermatology.com/news/case-study-ulcer-at-corner-of-mouth-may-be-first-sign-of-monkeypox-virus/2461429/Recent infection with monkeypox virus may initially present with an ulcer at the corner of the mouth, according to a case study of a 51-year-old HIV-positive patient published in Deutsches Ärzteblatt international</
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- Lullage Launches in US on International Skin Pigmentation Dayhttps://practicaldermatology.com/news/lullage-launches-in-us-on-international-skin-pigmentation-day/2461213/Lullage, known as Bella Aurora in Europe and Asia, celebrates International Skin Pigmentation Day to raise awareness about the prevalence of skin pigmentation conditions and the
- Differin Doubles Down on Retinoid Education Week with New Campaign Launchhttps://practicaldermatology.com/news/differin-doubles-down-on-retinoid-education-week-with-new-campaign-launch/2461100/Differin Gel is launching a digital and audio marketing campaign that will culminate in a strategic partnership with Acast Creative and the
- Galderma Completes Alastin Acquisitionhttps://practicaldermatology.com/news/galderma-completes-alastin-acquisition/2461026/Having received antitrust clearance from US authorities, Galderma has completed the acquisition of Alastin Skincare®, Inc., a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispens